GlassScriptPhysician profile
Jennifer Samson
NPI 1609253616
$3,119.53
in general payments reported to CMS, 2019-2025
21 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $721 · 2023: $589 · 2024: $711 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.41 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.32 | 2021-2025 | |
| Genzyme Corporation | $398.58 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $313.63 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $240.11 | 2021-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $232.12 | 2021-2025 | Taltz, Ebglyss |
| Pfizer INC. | $202.58 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $185.64 | 2021-2025 | Libtayo |
| Amgen INC. | $170.30 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $128.98 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $127.17 | 2021-2024 | Adbry |
| Dermavant Sciences, INC. | $90.31 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $73.84 | 2023-2024 | Tremfya |
| Galderma Laboratories, L.P. | $72.89 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.29 | 2021-2024 | Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $44.25 | 2023 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $41.75 | 2021 | |
| Mayne Pharma Commercial LLC | $41.67 | 2025 | |
| Ucb, INC. | $21.09 | 2025 | Bimzelx |
| Verrica Pharmaceuticals INC. | $20.70 | 2024 | Ycanth |
| Epi Health, LLC | $15.69 | 2022 | |
| Genentech USA, INC. | $15.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Samson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.